-+ 0.00%
-+ 0.00%
-+ 0.00%

Circio Collaborates with Solid Biosciences to Develop Genetic Heart Disease Gene Therapy

MT Newswires·11/11/2026 01:40:03
Listen to the news
01:40 AM EST, 11/11/2026 (MT Newswires) -- Norway-listed biotechnology company Circio Holding (CRNA.OL) partnered with US-based Solid Biosciences to combine their respective platforms to develop systemic gene therapy for genetic heart disease. Under the research collaboration, Circio's circular RNA gene expression platform, circVec, will integrate with Solid's adeno-associated virus capsid, Polaris-101TM, according to a Wednesday release. The technologies will be combined to evaluate potential synergies in vitro and in vivo.